|
1.
|
Hamada T, Wakamatsu T, Miyahara M, et al:
MUC4: a novel prognostic factor of oral squamous cell carcinoma.
Int J Cancer. 130:1768–1776. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Warnakulasuriya S: Global epidemiology of
oral and oropharyngeal cancer. Oral Oncol. 45:309–316. 2009.
View Article : Google Scholar
|
|
3.
|
Newman DJ and Cragg GM: Natural products
as sources of new drugs over the 30 years from 1981 to 2010. J Nat
Prod. 75:311–335. 2012.PubMed/NCBI
|
|
4.
|
Fried LE and Arbiser JL: Honokiol, a
multifunctional anti-angiogenic and antitumor agent. Antioxid Redox
Signal. 11:1139–1148. 2009. View Article : Google Scholar
|
|
5.
|
Fujita M, Itokawa H and Sashida Y: Studies
on the components of Magnolia obovata Thunb. 3. Occurrence
of magnolol and honokiol in M. obovata and other allied
plants. Yakugaku Zasshi. 93:429–434. 1973.(In Japanese).
|
|
6.
|
Teng CM, Chen CC, Ko FN, et al: Two
antiplatelet agents from Magnolia officinalis. Thromb Res.
50:757–765. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Liou KT, Lin SM, Huang SS, Chih CL and
Tsai SK: Honokiol ameliorates cerebral infarction from
ischemia-reperfusion injury in rats. Planta Med. 69:130–134. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Lo YC, Teng CM, Chen CF, Chen CC and Hong
CY: Magnolol and honokiol isolated from Magnolia officinalis
protect rat heart mitochondria against lipid peroxidation. Biochem
Pharmacol. 47:549–553. 1994.
|
|
9.
|
Kuribara H, Kishi E, Hattori N, Yuzurihara
M and Maruyama Y: Application of the elevated plus-maze test in
mice for evaluation of the content of honokiol in water extracts of
magnolia. Phytother Res. 13:593–596. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Battle TE, Arbiser J and Frank DA: The
natural product honokiol induces caspase-dependent apoptosis in
B-cell chronic lymphocytic leukemia (B-CLL) cells. Blood.
106:690–697. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Shigemura K, Arbiser JL, Sun SY, et al:
Honokiol, a natural plant product, inhibits the bone metastatic
growth of human prostate cancer cells. Cancer. 109:1279–1289. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Garcia A, Zheng Y, Zhao C, et al: Honokiol
suppresses survival signals mediated by Ras-dependent phospholipase
D activity in human cancer cells. Clin Cancer Res. 14:4267–4274.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Deng J, Qian Y, Geng L, et al: Involvement
of p38 mitogen-activated protein kinase pathway in honokiol-induced
apoptosis in a human hepatoma cell line (hepG2). Liver Int.
28:1458–1464. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Li Z, Liu Y, Zhao X, et al: Honokiol, a
natural therapeutic candidate, induces apoptosis and inhibits
angiogenesis of ovarian tumor cells. Eur J Obstet Gynecol Reprod
Biol. 140:95–102. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Bai X, Cerimele F, Ushio-Fukai M, et al:
Honokiol, a small molecular weight natural product, inhibits
angiogenesis in vitro and tumor growth in vivo. J Biol Chem.
278:35501–35507. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Sheu ML, Chiang CK, Tsai KS, et al:
Inhibition of NADPH oxidase-related oxidative stress-triggered
signaling by honokiol suppresses high glucose-induced human
endothelial cell apoptosis. Free Radic Biol Med. 44:2043–2050.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Lee J, Jung E, Park J, et al:
Anti-inflammatory effects of magnolol and honokiol are mediated
through inhibition of the downstream pathway of MEKK-1 in NF-kappaB
activation signaling. Planta Med. 71:338–343. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Tse AK, Wan CK, Shen XL, Yang M and Fong
WF: Honokiol inhibits TNF-alpha-stimulated NF-kappaB activation and
NF-kappaB-regulated gene expression through suppression of IKK
activation. Biochem Pharmacol. 70:1443–1457. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Li L and Davie JR: The role of Sp1 and Sp3
in normal and cancer cell biology. Ann Anat. 192:275–283. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Hirano T, Gotoh M and Oka K: Natural
flavonoids and lignans are potent cytostatic agents against human
leukemic HL-60 cells. Life Sci. 55:1061–1069. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Yang SE, Hsieh MT, Tsai TH and Hsu SL:
Down-modulation of Bcl-XL, release of cytochrome c and sequential
activation of caspases during honokiol-induced apoptosis in human
squamous lung cancer CH27 cells. Biochem Pharmacol. 63:1641–1651.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Abdelrahim M, Smith R III, Burghardt R and
Safe S: Role of Sp proteins in regulation of vascular endothelial
growth factor expression and proliferation of pancreatic cancer
cells. Cancer Res. 64:6740–6749. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Ishibashi H, Nakagawa K, Onimaru M, et al:
Sp1 decoy transfected to carcinoma cells suppresses the expression
of vascular endothelial growth factor, transforming growth factor
beta1, and tissue factor and also cell growth and invasion
activities. Cancer Res. 60:6531–6536. 2000.
|
|
24.
|
Kong LM, Liao CG, Fei F, Guo X, Xing JL
and Chen ZN: Transcription factor Sp1 regulates expression of
cancer-associated molecule CD147 in human lung cancer. Cancer Sci.
101:1463–1470. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Chuang JY, Wu CH, Lai MD, Chang WC and
Hung JJ: Overexpression of Sp1 leads to p53-dependent apoptosis in
cancer cells. Int J Cancer. 125:2066–2076. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Choi ES, Shim JH, Jung JY, et al:
Apoptotic effect of tolfenamic acid in androgen
receptor-independent prostate cancer cell and xenograft tumor
through specificity protein 1. Cancer Sci. 102:742–748. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Shim JH, Shin JA, Jung JY, et al:
Chemopreventive effect of tolfenamic acid on KB human cervical
cancer cells and tumor xenograft by downregulating specificity
protein 1. Eur J Cancer Prev. 20:102–111. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Davie JR, He S, Li L, et al: Nuclear
organization and chromatin dynamics - Sp1, Sp3 and histone
deacetylases. Adv Enzyme Regul. 48:189–208. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Grinstein E, Jundt F, Weinert I, Wernet P
and Royer HD: Sp1 as G1 cell cycle phase specific transcription
factor in epithelial cells. Oncogene. 21:1485–1492. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Chen F, Zhang F, Rao J and Studzinski GP:
Ectopic expression of truncated Sp1 transcription factor prolongs
the S phase and reduces the growth rate. Anticancer Res.
20:661–667. 2000.PubMed/NCBI
|
|
31.
|
Blume SW, Snyder RC, Ray R, Thomas S,
Koller CA and Miller DM: Mithramycin inhibits SP1 binding and
selectively inhibits transcriptional activity of the dihydrofolate
reductase gene in vitro and in vivo. J Clin Invest. 88:1613–1621.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Porter PL, Malone KE, Heagerty PJ, et al:
Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and
in combination, correlate with survival in young breast cancer
patients. Nat Med. 3:222–225. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Abbas T and Dutta A: p21 in cancer:
intricate networks and multiple activities. Nat Rev Cancer.
9:400–414. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Sherr CJ and Roberts JM: CDK inhibitors:
positive and negative regulators of G1-phase progression. Genes
Dev. 13:1501–1512. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Murray AW: Recycling the cell cycle:
cyclins revisited. Cell. 116:221–234. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Albanese C, Johnson J, Watanabe G, et al:
Transforming p21ras mutants and c-Ets-2 activate the cyclin D1
promoter through distinguishable regions. J Biol Chem.
270:23589–23597. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Lee RJ, Albanese C, Stenger RJ, et al:
pp60(v-src) induction of cyclin D1 requires collaborative
interactions between the extracellular signal-regulated kinase,
p38, and Jun kinase pathways. A role for cAMP response
element-binding protein and activating transcription factor-2 in
pp60(v-src) signaling in breast cancer cells. J Biol Chem.
274:7341–7350. 1999.
|
|
38.
|
Shtutman M, Zhurinsky J, Simcha I, et al:
The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway.
Proc Natl Acad Sci USA. 96:5522–5527. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Weinstein IB: Relevance of cyclin D1 and
other molecular markers to cancer chemoprevention. J Cell Biochem
(Suppl). 25:23–28. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Li F: Survivin study: what is the next
wave? J Cell Physiol. 197:8–29. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Xu R, Zhang P, Huang J, Ge S, Lu J and
Qian G: Sp1 and Sp3 regulate basal transcription of the survivin
gene. Biochem Biophys Res Commun. 356:286–292. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Chun JY, Hu Y, Pinder E, Wu J, Li F and
Gao AC: Selenium inhibition of survivin expression by preventing
Sp1 binding to its promoter. Mol Cancer Ther. 6:2572–2580. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Yoon JH, Werneburg NW, Higuchi H, et al:
Bile acids inhibit Mcl-1 protein turnover via an epidermal growth
factor receptor/Raf-1-dependent mechanism. Cancer Res.
62:6500–6505. 2002.PubMed/NCBI
|
|
44.
|
Okaro AC, Deery AR, Hutchins RR and
Davidson BR: The expression of antiapoptotic proteins Bcl-2,
Bcl-X(L), and Mcl-1 in benign, dysplastic, and malignant biliary
epithelium. J Clin Pathol. 54:927–932. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Akgul C: Mcl-1 is a potential therapeutic
target in multiple types of cancer. Cell Mol Life Sci.
66:1326–1336. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46.
|
Andersson Y, Juell S and Fodstad O:
Downregulation of the antiapoptotic MCL-1 protein and apoptosis in
MA-11 breast cancer cells induced by an anti-epidermal growth
factor receptor-pseudomonas exotoxin a immunotoxin. Int J Cancer.
112:475–483. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
47.
|
Chetoui N, Sylla K, Gagnon-Houde JV, et
al: Down-regulation of mcl-1 by small interfering RNA sensitizes
resistant melanoma cells to fas-mediated apoptosis. Mol Cancer Res.
6:42–52. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48.
|
Wei SH, Dong K, Lin F, et al: Inducing
apoptosis and enhancing chemosensitivity to gemcitabine via RNA
interference targeting Mcl-1 gene in pancreatic carcinoma cell.
Cancer Chemother Pharmacol. 62:1055–1064. 2008. View Article : Google Scholar : PubMed/NCBI
|
